|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||63.00 - 63.00|
|52 Week Range||50.00 - 84.50|
|Beta (5Y Monthly)||0.75|
|PE Ratio (TTM)||30.27|
|Forward Dividend & Yield||1.47 (2.33%)|
|Ex-Dividend Date||Mar 29, 2020|
|1y Target Est||N/A|
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 31) * Athersys Inc (NASDAQ: ATHX) * Forty Seven Inc (NASDAQ: FTSV) * Ra Pharmaceuticals Inc (NASDAQ: RARX) * Quidel Corporation (NASDAQ: QDEL)Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 31) * Aikido Pharma Inc (NASDAQ: AIKI) * BIOLASE Inc (NASDAQ: BIOL) * Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) * Gritstone Oncology Inc (NASDAQ: GRTS) * Neovasc Inc (NASDAQ: NVCN)(moved in reaction to its fourth quarter results) * Opko Health Inc. (NASDAQ: OPK) * Phio Pharmaceuticals Corp (NASDAQ: PHIO)(announced $4 million registered offering) * Second Sight Medical Products Inc (NASDAQ: EYES)Related Link: Amarin Analysts React To Vascepa Patent Loss, See Small Chance Of Overturning JudgmentStocks In Focus Inflarx Begins Human Testing Of Lead Drug For COVID-19-induced Pneumonia German biopharma Inflarx NV (NASDAQ: IFRX) said it has enrolled and dosed the first patient into a randomized clinical trial investigating the safety and efficacy of IFX-1, its monoclonal anti-C5a antibody in patients with severe COVID-19-induced pneumonia. The trial is being initiated in the Netherlands.The decision to initiate human testing follows initial positive human data from two patients suffering from COVID-19-induced pneumonia, who were treated with BDB-001, an anti-C5a antibody produced from BDB from the IFX-1 cell line, in China.The company said it plans to initiate additional centers in Germany and potentially other European countries.In pre-market trading Wednesday, InflaRx shares were jumping 114.66% to $8.20.Emergent Biosolutions To Provide CDMO Services For Novavax's Flu Vaccine Candidate Novavax, Inc. (NASDAQ: NVAX) and Emergent Biosolutions Inc (NYSE: EBS) announced an agreement, whereby the latter would provide molecule-to-market contract development and manufacturing to produce the former's recombinant quadrivalent seasonal influenza vaccine candidate with its proprietary Matrix-M adjuvant.Novavax recently announced positive results for the late-stage trial that evaluated the vaccine candidate.Novavax shares were adding 3.09% to $14 in pre-market trading.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.Mesoblast's Regulatory Filing For Graft Vs. Host Disease Drug Accepted For Priority Review Mesoblast limited (NASDAQ: MESO) said the FDA has accepted for priority review its BLA for Ryoncil, its allogeneic cell therapy for the treatment of children with steroid-refractory acute graft versus host disease. The PDUFA date has been set for Sept. 30, the company noted.View more earnings on IFRXThe stock was advancing 8.45% to $4.75 in pre-market trading.Eisai To Co-develop And Commercialize Seikagaku's Osteoarthritis Drug In China Eisai Co., Ltd (OTC: ESALY) announced an agreement with Seikagaku for co-developing and marketing of SI-613 in China. SI-613 is a therapeutic agent for osteoarthritis discovered by Seikagaku.Chembio Launches Serological COVID-19 Detection Test In U.S. Chembio Diagnostics Inc (NASDAQ: CEMI) said it has launched in the U.S. the rapid DPP COVID-19 serological point-of-care test for the detection of IgM and IgG antibodies."These results can be obtained within 15 minutes from a simple finger stick utilizing Chembio's MicroReader 1 and MicroReader 2 analyzers which are produced by Chembio Germany," the company said.The stock was jumping 23.05% to $6.30 in after-hours trading.Becton Dickinson Releases COVID-19 Test Developed By BioMedomics Medtech company Becton Dickinson and Co (NYSE: BDX) and privately held diagnostics company BioMedomics announced the release of a new point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19 in as little as 15 minutes.The new test developed and manufactured by BioMedomics will be available through BD and distributed exclusively by Henry Schein, Inc. (NASDAQ: HSIC) to health care providers throughout the U.S.BD shares were adding 0.97% to $232 in pre-market trading.Ultragenyx Out-licenses Gene Therapy Platforms And In-licenses Gene Therapy Vectors Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) announced a strategic partnership and non-exclusive license and technology access agreement with DAIICHI SANKYO/S ADR (OTC: DSNKY) for its AAV-based gene therapy manufacturing technologies, namely its HeLa PCL and HEK293 transient transfection manufacturing technology platforms.The agreement provides for Daiichi Sankyo making an upfront payment of $125 million and an equity investment amounting to $75 million at about $60 per share in Ultragenyx. Daiichi Sankyo will pay an additional $25 million upon completion of the technology transfer of the HeLa PCL and HEK293 platforms as well as single-digit royalties on net sales of products manufactured in either system.Separately, Ultragenyx and Regenxbio Inc (NASDAQ: RGNX) announced a new exclusive, worldwide license agreement, extending the companies' existing gene therapy partnership. Under the agreement, REGENXBIO has granted Ultragenyx an exclusive, worldwide license, with rights to sublicense, to its NAV AAV8 and AAV9 vectors for the development and commercialization of gene therapy treatments for a rare metabolic disorder. Regenxbio will be compensated with an upfront payment of $7 million, ongoing fees, milestone payments, and royalties on net sales of products incorporating the licensed intellectual property.On The Radar Earnings Ascendis Pharma A/S (NASDAQ: ASND) (after the market close)See more from Benzinga * The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test * 10 Small-To-Mid-Cap Biotech Ideas For When The Coronavirus Fades(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Eisai Co. Ltd. said Thursday that it would pull its weight-loss drug Belviq off the market in the U.S. A long-term trial, which studied the drug's cardiovascular impact, was required as part of the Food and Drug Administration approval in 2012. This study found that people taking the drug reported higher rates of cancer than those taking the placebo. Eisai said it still believes Belviq has a positive benefit-risk profile for the patients for which it is indicated but would still pull the drug from the market. "Eisai's interpretation of the data from the Camellia-Timi 61 trial differs from that of the FDA," the company said in a news release. Eisai's stock is up 4% over the past year, compared to the S&P 500 , which has gained 22%.
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 13.) Anavex Life Sciences Corp (NASDAQ: AVXL ) ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 4) Agile Therapeutics Inc (NASDAQ: AGRX )(follow-on rally ...
Shares in Eisai Co , Biogen's Japanese partner in the drug, were quoted up 18% to the daily limit high of 6,534 yen in Tokyo trading. The field of experimental Alzheimer's treatments is littered with high-profile failures, with many major drugmakers abandoning the race to develop a medicine for a disease that makes up 60%-70% of an estimated 50 million dementia cases globally. Any medicine that effectively treats the disease is likely to become one of the world's top-selling drugs and could be transformative for Biogen, which is facing multiple challenges over its product pipeline.
Biogen stock popped in relief Friday after the biotech company scrapped several tests in Alzheimer's treatment for a drug known as elenbecestat. It was being developed with Japan's Eisai.
Biogen Inc and Eisai Co Ltd are abandoning two late-stage trials for their Alzheimer's treatment in a widely anticipated move that comes months after the companies scrapped trials of another drug for the memory-robbing disease. The companies said on Friday the decision was based on the results of a review conducted by a data safety monitoring board, which recommended discontinuing the trials as benefits from the treatment, elenbecestat, did not outweigh its risks. Shares of Biogen were up 2.3% at $237.60 as some analysts said ending the trial would save the company costs associated with running it through its completion.
Japanese drug maker Eisai Co., Ltd (OTC: ESALY ) has some positive news concerning one of its pipeline candidates. What Happened Eisai said the FDA has granted Breakthrough Therapy Designation for Lenvima, ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 22) Acasti Pharma Inc (NASDAQ: ACST ) Apellis Pharmaceuticals ...
Investors should keep tabs on these "focus events" from this quartet of U.S.-listed Japanese drugmakers that can make or break their treatments.
Alzheimer's treatment continues to confound biotech companies in the wake of Biogen and Eisai's decision to terminate two late-stage tests. But scientists say there's hope in new theories.
Comparing MRK’s and ABBV’s Outlook: Which Is the Better Pick?(Continued from Prior Part)Lenvima growth trendsIn the first quarter, Merck’s (MRK) and Eisai’s Lenvima reported solid uptake across multiple markets, driven mainly by demand in
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 30) VolitionRX Ltd (NYSE: VNRX ) ZEALAND PHARMA/S ADR ...